Dr. Reddy’s Laboratories announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to advanced GLP-1 receptor agonistbased therapy for the management of type 2 diabetes in India.
Dr. Reddy’s has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company’s Day-1 entry into the segment upon patent expiry, demonstrating its readiness to serve unmet patient needs in India.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Mar 21 2026 | 10:31 AM IST
